Natalie Allen

Natalie Allen


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Diagnostics
Verified
Journal Article
Open access
PDF file
NANatalie Allen
Natalie Allen
AGAnshu Gupta
Anshu Gupta
Diabetes technology has continually evolved over the years to improve quality of life and ease of care for affected patients. Frequent blood glucose (BG) checks and multiple daily insulin injections have become standard of care in Type 1 diabetes (T1DM) management. Continuous glucose monitors (CGM) allow patients to observe and discern trends in their glycemic control. These devices improve quality of life for parents and caregivers with preset alerts for hypoglycemia. Insulin pumps have continued to improve and innovate since their emergence into the market. Hybrid closed-loop systems have harnessed the data gathered with CGM use to aid in basal insulin dosing and hypoglycemia prevention. As technology continues to progress, patients will likely have to enter less and less information into their pump system manually. In the future, we will likely see a system that requires no manual patient input and allows users to eat throughout the day without counting carbohydrates or entering in any blood sugars. As technology continues to advance, endocrinologists and diabetes providers need to stay current to better guide their patients in optimal use of emerging management tools.

21 November 2021 in Obesity
Verified
Journal Article
Closed access
PDF file
NANatalie Allen
Natalie Allen
LELaahirie Edupuganti
Laahirie Edupuganti
DEDavid J. Edwards
David J. Edwards
NJNicole R. Jimenez
Nicole R. Jimenez
GBGregory A. Buck
Gregory A. Buck
JFJennifer M. Fettweis
Jennifer M. Fettweis

17 May 2021 in Current Opinion in Pediatrics
Verified
Journal Article
Closed access
NANatalie Allen
Natalie Allen
KKKanthi Bangalore Krishna
Kanthi Bangalore Krishna
PLPeter A. Lee
Peter A. Lee
Purpose of review: In this review, we outline the usage and formulations of gonadotropin-releasing hormone analogs (GnRHas) in central precocious puberty (CPP), short stature, and gender diverse individuals, as well as adverse effects, long-term outcomes, and monitoring of therapy. There is a particular focus on citing references published within the last 24 months. Recent findings: Long-acting formulations of GnRHa now include Federal Drug Administration approval for subcutaneous injections. Significant adverse events continue to be rarely reported; extremely rare events include arterial hypertension and pseudotumor cerebri. There continue to be no significant long-term consequences including the impact upon body mass index and bone mineral density, which appear to be transient. GnRHas have been used in differences of sexual development (DSD) and increasingly in the treatment of adolescent transgender individuals. Summary: GnRHas remain as the only fully efficacious therapy for CPP and effectively suppress pubertal hormones in other situations. The use of GnRHa therapy in gender incongruent individuals has proven beneficial and has become a standard of care, whereas use in those with DSDs should still be considered experimental. Video http://links.lww.com/MOP/A62.

1 September 2023 in JCEM Case Reports
Verified
Journal Article
Open access
PDF file
YYYunting Yu
Yunting Yu
PLPeter A Lee
Peter A Lee
LHLina Huerta-Saenz
Lina Huerta-Saenz
NANatalie Allen
Natalie Allen
Differences of sex development (DSDs) are a spectrum of congenital clinical conditions involving the development of gonadal, chromosomal, and anatomical sex. The physical presentation provides incomplete clues because underlying etiologies may present with similar findings. We describe an 8-year-old boy from the Dominican Republic originally diagnosed with congenital adrenal hyperplasia (CAH). He was prescribed oral hydrocortisone and fludrocortisone, with irregular adherence. During infancy, he had human chorionic gonadotropin injections to stimulate phallic growth. After migrating to the United States, medications became depleted but without adrenal crisis. Laboratory testing with high-dose adrenocorticotropin stimulation study ruled out CAH. Careful examination noted an underdeveloped bifid scrotum, bilaterally undescended testicles, a 2-cm phallus, severe penoscrotal hypospadias, and chordee. Subsequently, he had a 2-stage bilateral orchiopexy and surgical repair of penoscrotal hypospadias and chordee. Genetic testing for 46,XY DSD revealed a novel, dominant, heterozygous, likely pathogenic variant (c.102 + 1G > C) in the NR5A1 gene associated with severe phenotype of undervirilized male. This case illustrates the crucial role of molecular genetic testing for the diagnosis of 46,XY DSDs and a novel NR5A1 gene variant.

11 January 2020 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
NANatalie Allen
Natalie Allen
NDN. Desai
N. Desai
CSC. Song
C. Song
JYJ. Yu
J. Yu
UPU. Prasad
U. Prasad
GFG. Francis
G. Francis

23 February 2024 in Endocrinology and Metabolism Clinics of North America
Verified
Journal Article
Closed access
NANatalie Allen
Natalie Allen
PKPaul B. Kaplowitz
Paul B. Kaplowitz